{"preliminary_commentary":{"by_channel":{"x_thread":10,"podcast":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02568267\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["entrectinib"]],"indication":"advanced NTRK1/2/3, ROS1 or ALK fusion-positive solid tumors","name":"STARTRK-2","nct_id":"NCT02568267","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=startrk-2-nct02568267. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"STARTRK-2","arms":[{"description":"Oral entrectinib (RXDX-101)","label":"NTRK1/2/3-rearranged NSCLC","type":"EXPERIMENTAL"},{"description":"Oral entrectinib (RXDX-101)","label":"ROS1-rearranged NSCLC","type":"EXPERIMENTAL"},{"description":"with CNS-only progression previously treated with crizotinib (NOTE: The ALK-rearranged portion of this arm is now closed to enrollment.)\n\nOral entrectinib (RXDX-101)","label":"ALK- or ROS1-rearranged NSCLC","type":"EXPERIMENTAL"},{"description":"Oral entrectinib (RXDX-101)","label":"NTRK/1/2/3-rearranged mCRC","type":"EXPERIMENTAL"},{"description":"Oral entrectinib (RXDX-101)","label":"ROS1-rearranged mCRC","type":"EXPERIMENTAL"},{"description":"Oral entrectinib (RXDX-101)","label":"ALK-rearranged mCRC","type":"EXPERIMENTAL"},{"description":"Oral entrectinib (RXDX-101)","label":"NTRK1/2/3-rearranged other solid tumor","type":"EXPERIMENTAL"},{"description":"Oral entrectinib (RXDX-101)","label":"ROS1-rearranged other solid tumor","type":"EXPERIMENTAL"},{"description":"Oral entrectinib (RXDX-101)","label":"ALK-rearranged other solid tumor","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"conditions":["Breast Cancer","Cholangiocarcinoma","Colorectal Cancer","Head and Neck Neoplasms","Lymphoma, Large-Cell, Anaplastic","Melanoma","Neuroendocrine Tumors","Non-Small Cell Lung Cancer","Ovarian Cancer","Pancreatic Cancer","Papillary Thyroid Cancer","Primary Brain Tumors","Renal Cell Carcinoma","Sarcomas","Salivary Gland Cancers","Adult Solid Tumor"],"enrollment":{"count":534,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Entrectinib","otherNames":["RXDX-101"],"type":"DRUG"}],"last_update":"2026-08-25","lead_sponsor":"Hoffmann-La Roche","official_title":"An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate","timeFrame":"Approximately 24 months"}],"references":[{"citation":"Ajani JA, D'Amico TA, Bentrem DJ, Corvera CU, Das P, Enzinger PC, Enzler T, Gerdes H, Gibson MK, Grierson P, Gupta G, Hofstetter WL, Ilson DH, Jalal S, Kim S, Kleinberg LR, Klempner S, Lacy J, Lee B, Licciardi F, Lloyd S, Ly QP, Matsukuma K, McNamara M, Merkow RP, Miller AM, Mukherjee S, Mulcahy MF, Perry KA, Pimiento JM, Reddi DM, Reznik S, Roses RE, Strong VE, Su S, Uboha N, Wainberg ZA, Willett CG, Woo Y, Yoon HH, McMillian NR, Stein M. Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 May;23(5):169-191. doi: 10.6004/jnccn.2025.0022.","pmid":"40341199","type":"DERIVED"},{"citation":"Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.","pmid":"40086048","type":"DERIVED"},{"citation":"Yu Y, Fan Y, Dong X, Li J, Yu Y, Zhao J, Tao S, Chen Y, Chen M, Liu Y, Xu J, Zhu Q, Hu X, Lu S. Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison. Lung Cancer. 2024 Dec;198:108018. doi: 10.1016/j.lungcan.2024.108018. Epub 2024 Nov 10.","pmid":"39549678","type":"DERIVED"},{"citation":"Choudhury NJ, Jun Woo H, Chen M, Shah R, Donoghue M, Berger M, Drilon A. Serial Cell-Free DNA Sequencing in ROS1 Fusion-Positive Lung Cancers During Treatment With Entrectinib. JCO Precis Oncol. 2024 Jun;8:e2300721. doi: 10.1200/PO.23.00721.","pmid":"38848521","type":"DERIVED"},{"citation":"Yokota T, Yukino H, Doi M, Ohori H. Real-world experience of tropomyosin receptor kinase inhibition with entrectinib in ETV6-NTRK3 positive metastatic salivary secretory carcinoma: A case series. Head Neck. 2023 May;45(5):E10-E15. doi: 10.1002/hed.27346. Epub 2023 Mar 16.","pmid":"36924196","type":"DERIVED"},{"citation":"Sullivan WG, Hatswell AJ. Letter re: 'Intrapatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications'. ESMO Open. 2021 Dec;6(6):100282. doi: 10.1016/j.esmoop.2021.100282. Epub 2021 Oct 28. No abstract available.","pmid":"34924145","type":"DERIVED"},{"citation":"Doebele RC, Perez L, Trinh H, Martinec M, Martina R, Riehl T, Krebs MG, Meropol NJ, Wong WB, Crane G. Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC. J Comp Eff Res. 2021 Dec;10(17):1271-1282. doi: 10.2217/cer-2021-0131. Epub 2021 Aug 24.","pmid":"34427452","type":"DERIVED"},{"citation":"Dziadziuszko R, Krebs MG, De Braud F, Siena S, Drilon A, Doebele RC, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Farago AF, Lin CC, Karapetis CS, Li YC, Day BM, Chen D, Wilson TR, Barlesi F. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 Apr 10;39(11):1253-1263. doi: 10.1200/JCO.20.03025. Epub 2021 Mar 1.","pmid":"33646820","type":"DERIVED"},{"citation":"Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC; trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11.","pmid":"31838015","type":"DERIVED"},{"citation":"Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.","pmid":"31838007","type":"DERIVED"},{"citation":"Sigal D, Tartar M, Xavier M, Bao F, Foley P, Luo D, Christiansen J, Hornby Z, Maneval EC, Multani P. Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer. J Natl Compr Canc Netw. 2017 Nov;15(11):1317-1322. doi: 10.6004/jnccn.2017.7029.","pmid":"29118225","type":"DERIVED"}],"start_date":{"date":"2015-11-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","url":"https://clinicaltrials.gov/study/NCT02568267"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/startrk-2-nct02568267"}